Radiation Dose of the P-Glycoprotein Tracer C-11-Laniquidar

A. Postnov, F.E. Froklage, A. van Lingen, J.C. Reijneveld, N.H. Hendrikse, A.D. Windhorst, R.C. Schuit, P.A.J. Eriksson, A.A. Lammertsma, M.C. Huisman

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)


Resistance to current drug therapy is an important issue in the treatment of epilepsy. Inadequate access of central nervous system drugs to their targets in the brain may be caused by overexpression or overactivity of multidrug transporters, such as P-glycoprotein (P-gp), at the blood-brain barrier. Laniquidar, an inhibitor of P-gp, has been labeled with
Original languageEnglish
Pages (from-to)2101-2103
JournalJournal of nuclear medicine
Issue number12
Publication statusPublished - 2013

Cite this